Table 2.

Associations between selected clinical or reproductive factors and EIN status at index biopsy

	EIN Classification
	Benign		EIN		Cancer
	N	%	N	%	N	%	P-value
Menarche (in years)							0.30
<12	48	17%	12	4%	2	1%
12–13	95	33%	53	19%	8	3%
14+	45	16%	17	6%	4	1%
Ever had irregular menses							0.02
Yes	110	56%	54	27%	8	3%
No	19	10%	6	2%	0	0%
Ever pregnant							0.007
No	19	5%	23	6%	5	1%
Yes	211	59%	84	23%	18	5%
No. of live births							0.30
0–1	40	11%	21	6%	4	1%
2–3	115	32%	53	15%	11	3%
4+	75	21%	33	9%	8	2%
BMI (body mass index; kg/m2)							0.02
<25	58	17%	26	8%	8	2%
25–29	53	15%	17	5%	4	1%
30–34	46	14%	10	3%	4	1%
35–39	30	9%	13	4%	2	1%
40+	26	8%	34	10%	4	1%
Menopausal status at index biopsy							0.87
Pre/peri	151	43%	66	19%	8	2%
Postmenopausal	75	21%	36	10%	15	4%
Age at menopause (in yrs)							0.87
<=45	11	3%	7	2%	0	0%
46–52	37	11%	16	5%	8	2%
52+	23	7%	8	2%	6	2%
Ever had diabetes							0.03
No	158	52%	66	22%	15	5%
Yes	39	13%	24	9%	4	1%
Smoking status at index biopsy							0.87
Never	134	40%	61	18%	10	3%
Former	51	15%	22	7%	6	2%
Current	26	8%	20	6%	4	1%
Oral contraceptive use							0.08
Never	137	42%	61	19%	18	6%
Ever	69	21%	34	11%	4	1%
HT use at index biopsy							<0.0001
Never	96	31%	44	14%	11	4%
Former	41	13%	21	7%	3	1%
Current	62	20%	27	9%	7	2%
HT use at diagnosis/censor							<0.0001
Never	28	8%	19	6%	6	2%
Former	99	29%	42	12%	4	1%
Current	92	27%	42	12%	11	3%
Type of treatment for EH							0.48
None	28	8%	4	1%	2	1%
MPA-based	202	56%	103	29%	21	6%

HT, menopausal hormone therapy. MPA, medroxyprogesterone acetate.

P-value <0.05 indicates a statistically significant association between that clinical or reproductive factor and EIN classification.

Table combines 126 cases and 234 controls with EIN classification of benign, EIN, or cancer.